木瓜直播

Ian Ingram

Ian Ingram

Authors >

Ian Ingram

Ian Ingram joined 木瓜直播 in 2018 as Deputy Managing Editor, and covers oncology for the site. Ian Ingram has been a medical editor for the past decade. Prior to joining 木瓜直播, he was managing editor of Cancer Network, directing the website鈥檚 news coverage and video production. Ian has also worked as a fact-checker, was an assistant editor at Narrative Magazine, and a manuscript reader at the Paris Review. He holds a B.A. in journalism from Purchase College. Ian lives in Connecticut, enjoys tennis, and almost always bowls a perfect game.

Connect:

email image

Latest from Ian Ingram

FDA APPROVED lebrikizumab (Ebglyss) over a photo of a woman with a severe atomic dermatitis rash on her face.

Lebrikizumab Wins FDA Approval for Eczema

38% of patients treated with IL-13 blocker achieved clear or almost-clear skin at 16 weeks

ERS over a photo of Messe Wien Exhibition Congress Center in Vienna, Austria.

ERS Roundup: Air Filtration Succeeds in Reducing Infections

Other studies looked at steroids for kids with pneumonia and a link between asthma and fertility

ERS over a photo of the Messe Wien Exhibition Congress Center in Vienna, Austria.

Inhaled Antibiotic for Bronchiectasis Shows Benefit ... and Then It Doesn't

One negative trial in the phase III PROMIS program blamed squarely on the COVID-19 pandemic

FDA approved guselkumab (Tremfya) over a computer rendering of ulcerative colitis.

FDA Expands Approval of IL-23 Drug to Ulcerative Colitis

In trials, guselkumab more than doubled remission rates versus placebo

ERS over a photo of Messe Wien Exhibition Congress Center in Vienna, Austria.

Cheap Antidepressant Flops for Severe Breathlessness in Trial

"We should be cautious about using drugs off-label," investigator says

ERS over a photo of Messe Wien Exhibition Congress Center in Vienna, Austria.

Burdensome Therapy for Severe Hypoxemia in COPD Patients Is Overkill, Trial Says

They'll "still have that ball and chain, but maybe we've lightened it a little bit," says expert

ERS over a photo of Messe Wien Exhibition Congress Center in Vienna, Austria.

Twice-Yearly Biologic Cuts Severe Asthma Exacerbation Rate in Half

Investigational depemokimab succeeds in patients with high blood eosinophil count

FDA APPROVED durvalumab (Imfinzi) over a computer rendering of a transparent body with lung cancer highlighted.

FDA Expands Durvalumab Label to Operable Lung Cancer

PD-L1 checkpoint inhibitor approved for use in NSCLC before and after surgery

FDA APPROVED seladelpar (Livdelzi) over a rendering of a transparent body with the gallbladder and bile duct highlighted.

FDA OKs New Option for Primary Biliary Cholangitis

Seladelpar improved biochemical response, ALP normalization versus placebo in phase III trial

A photo of a teen girl looking at her phone in a dark room.

Free Text Message Program Helps Teens Quit E-Cigarettes

First randomized trial to show a significant benefit for helping teens stop vaping

1

鈥�